Overview

The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with anti-IL-5 antibody has a prednisone-sparing effect in patients with symptomatic eosinophilic bronchitis (with or without asthma).
Phase:
Phase 2
Details
Lead Sponsor:
St. Joseph's Healthcare Hamilton
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies